Company news
AIM ImmunoTech Inc. news in 2025
AIM ImmunoTech Inc.'s news releases, calls and decks from 2025, newest first.
AIM ImmunoTech Announces Stock Dividend
December 30, 2025
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
December 10, 2025
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
December 1, 2025
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
November 18, 2025
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
November 10, 2025
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
November 4, 2025
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
November 3, 2025
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
October 20, 2025
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
September 25, 2025
AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth
September 22, 2025
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
September 4, 2025
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 15, 2025
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
August 14, 2025
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)
August 6, 2025
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval
August 4, 2025
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering
July 31, 2025
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering
July 29, 2025
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
July 28, 2025
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
July 2, 2025
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
June 20, 2025
AIM ImmunoTech Resumes Trading on NYSE American
June 17, 2025
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
June 12, 2025
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
June 12, 2025
Calls in 2025
Decks in 2025
- Maxim Growth Conference Oct. 22-23, 2025
Conference · 20 slides · Oct 20, 2025
- Investor Presentation (August 2025)
Investor deck · 21 slides · August 2025